Rocket Pharmaceuticals gets FDA path to complete RP-A501 Danon disease pivotal trial
FDA clears Rocket Pharmaceuticals to continue its recalibrated RP-A501 pivotal trial, restoring a defined accelerated approval path in Danon disease.
Pharma & Biotech